PLYMOUTH, Mich.--(BUSINESS WIRE)--
Esperion Therapeutics, Inc. (Nasdaq:ESPR), a clinical-stage
biopharmaceutical company focused on developing and commercializing
first-in-class, oral, low-density lipoprotein cholesterol (LDL-C)
lowering therapies for the treatment of hypercholesterolemia, today
announced the appointment of Antonio M. Gotto Jr., M.D., DPhil as a
Director of the Company. Dr. Gotto will serve as a Class II director
with a term of office expiring at our 2015 annual meeting of
Dr. Gotto currently serves as Co-Chairman of the Board of Overseers of
the Joan and Sanford I. Weill Medical College of Cornell University and
Vice President of Cornell University. From January 1997 to December
2011, Dr. Gotto served as the Stephen and Suzanne Weiss Dean of the Joan
and Sanford I. Weill Medical College of Cornell University and Provost
for Medical Affairs of Cornell University. Previously, Dr. Gotto served
as J.S. Abercrombie Chair of Atherosclerosis and Lipoprotein Research
and Chairman and Professor of the Department of Medicine at Baylor
College of Medicine and Methodist Hospital. Dr. Gotto currently serves
as a member of the Institute of Medicine of the National Academy of
Sciences and a Fellow of the American Academy of Arts and Sciences. Dr.
Gotto is also a past president of the International Atherosclerosis
Society and a past president of the American Heart Association. Dr.
Gotto holds a B.A. degree from Vanderbilt University, a D.Phil. degree
in Biochemistry from Oxford University in England, where he was a Rhodes
Scholar, and an M.D. degree from Vanderbilt University School of
Medicine. He completed his residency training at Massachusetts General
Hospital in Boston, Massachusetts. Dr. Gotto is also a member of the
Board of Directors of Aegerion Pharmaceuticals, Inc.
Tim Mayleben, president and chief executive office of the Company, said,
"We are very pleased to welcome Dr. Gotto to the Esperion Board of
Directors. He has extensive experience in atherosclerosis and lipid
regulation and prior experience working with us at the original
Esperion. We welcome the strategic contributions Dr. Gotto will provide
as a board member and look forward to working with him."
"Throughout my professional career, I have been a supporter of and
participant in lipoprotein and atherosclerosis research. Thus, I am very
pleased to be joining the Esperion Board of Directors," said Dr. Gotto.
"I believe Esperion is well-positioned to make important contributions
in the basic and clinical development of novel products for lowering
LDL-cholesterol. This would be especially important for
statin-intolerant patients. I look forward to contributing to the
company's continued success."
About Esperion Therapeutics
Esperion Therapeutics, Inc. is a biopharmaceutical company focused on
the research, development and commercialization of therapies for the
treatment of patients with elevated levels of low-density lipoprotein
cholesterol (LDL-C) and other cardiometabolic risk factors. ETC-1002,
Esperion's lead product candidate, is a unique, first-in-class, orally
available, once-daily small molecule therapy designed to lower levels of
LDL-C and to avoid side effects associated with existing LDL-C lowering
therapies. ETC-1002 is targeted for statin intolerant patients with
elevated levels of LDL-C. Esperion has completed seven clinical studies
to date, including four Phase 2a studies, and has initiated a robust
Phase 2b clinical program. For more information, please visit www.esperion.com.
Forward Looking Statements
This press release contains forward-looking statements that are made
pursuant to the safe harbor provisions of the federal securities laws,
including, without limitation, statements regarding the development and
therapeutic potential of ETC-1002. Any statements contained in this
press release that are not statements of historical fact may be deemed
to be forward-looking statements. Forward-looking statements involve
risks and uncertainties that could cause Esperion's actual results to
differ significantly from those projected, including, without
limitation, the risk that unanticipated developments could interfere
with the development (and commercialization) of ETC-1002, as well as
other risks detailed in Esperion's filings with the Securities and
Exchange Commission, including our Quarterly Report on Form 10-Q filed
with the Securities and Exchange Commission on November 6, 2013. You are
cautioned not to place undue reliance on the forward-looking statements,
which speak only as of the date of this release. Esperion disclaims any
obligation or undertaking to update or revise any forward-looking
statements contained in this press release, other than to the extent
required by law.
Source: Esperion Therapeutics, Inc.